US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Palisade Bio, Inc. - Common Stock (NQ:PALI)

1.330 -0.020 (-1.48%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Palisade Bio, Inc. - Common Stock

News headline image
Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Eyes NYSE Uplisting as Polymetallic Discoveries Accelerate – More Stocks Inside
Via AB Newswire
News headline image
Loop Industries (NASDAQ: LOOP) Builds Global Momentum in Circular Textiles w/ Twist™ – More Stocks Inside
Via AB Newswire
News headline image
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
News headline image
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
News headline image
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148
Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of 
Via Spotlight Growth
News headline image
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Announces Reverse Stock Split
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Announces Executive Leadership Transition
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners
Dallas, Texas--(Newsfile Corp. - March 14, 2022) - Stonegate Capital Partners is hosting a... 
Via Newsfile